Search clinical trials for: Palbociclib

Total 370 results

Spanish Breast Cancer Research Group
Pfizer; AstraZeneca

Completed

Phase III Palbociclib With Endocrine Therapy vs. Capecitabine in HR+/HER2- MBC With Resistance to Aromatase Inhibitors (PEARL)

Metastatic Breast Cancer

Spain, Israel, Hungary, Austria
MedSIR
Pfizer

Completed

Neoadjuvant Letrozole and Palbociclib in Patients With Stage II-IIIB Breast Cancer, HR+, HER2 - (DxCARTES)

Breast Cancer

Spain, Portugal
Pfizer

Completed

A Study Of Oral Palbociclib (PD-0332991), A CDK4/6 Inhibitor, As Single Agent In Japanese Patients With Advanced Solid Tumors Or In Combination With Letrozole For The First-Line Treatment Of Postmenopausal Japanese Patients With ER (+) HER2 (-) Advanced Breast Cancer

Neoplasms | Breast Neoplasms

Japan
Weill Medical College of Cornell University

Withdrawn

CIMER: Combined Immunotherapies in Metastatic ER+ Breast Cancer (CIMER)

Breast Cancer
University of Michigan Rogel Cancer Center
Johns Hopkins University; Washington University School of Medicine; Northwestern... and other collaborators

Completed

A Phase II Study of Androgen Deprivation Therapy With or Without Palbociclib in RB-Positive Metastatic Prostate Cancer

Prostate Cancer

United States
St. Jude Children's Research Hospital
Pfizer

Terminated

Treatment With Combination Chemotherapy for Relapsed or Refractory Acute Lymphoblastic Leukemia

Acute Lymphoblastic Leukemia, in Relapse | Acute Lymphoblastic Leukemia With Failed Remission

United States
Istituti Clinici Scientifici Maugeri SpA

Completed

Patterns of Treatment and Outcome of Palbociclib Plus Endocrine Therapy

Female | Neoplasm Malignant | Breast

Italy
Pfizer

Completed

TREATMENT AND MONITORING PATTERNS AND CLINICAL OUTCOMES IN PATIENTS RECEIVING PALBOCICLIB COMBINATION TREATMENT (WITH AI OR FULVESTRANT) FOR HR+/HER2- A/MBC IN A COMMUNITY ONCOLOGY SETTING.

Breast Cancer

United States
Fondazione Michelangelo

Completed

"Neo-Adjuvant Treatment With Palbociclib: Effect on Ki67 and Apoptosis Before, During and After Treatment " (NA-PHER2)

Breast Neoplasms

Italy
Thomas Hatschek

Active, not recruiting

Neoadjuvant Response-guided Treatment of Slowly Proliferating Hormone Receptor Positive Tumors (PREDIX LumA)

Early-Stage Breast Carcinoma | Hormone Receptor Positive Tumor

Sweden
Jonsson Comprehensive Cancer Center

Completed

A Open Label Study of the Efficacy and Safety of PD0332991 a Selective Inhibitor of the Cyclin Dependent Kinases 4 and 6 in Patients With Recurrent Ovarian Cancer Demonstrating Rb-proficiency and Low p16 Expression

Ovarian Epithelial Carcinoma

United States
Merck Sharp & Dohme LLC

Completed

Imipenem/Relebactam/Cilastatin Versus Piperacillin/Tazobactam for Treatment of Participants With Bacterial Pneumonia (MK-7655A-014) (RESTORE-IMI 2)

Bacterial Pneumonia
Northwestern University
National Cancer Institute (NCI); Pfizer

Terminated

Palbociclib in Treating Patients With Metastatic HER-2 Positive Breast Cancer With Brain Metastasis

Stage IV Breast Cancer | Recurrent Breast Carcinoma | Estrogen Receptor Negative | HER2/Neu Negative | HER2/Neu Positive | Progesterone Receptor Negative | Breast Carcinoma Metastatic in the Brain

United States
Abramson Cancer Center of the University of Pennsylvania

Completed

PD0332991/Paclitaxel in Advanced Breast Cancer

Breast Cancer

United States
Grupo Español de Investigación en Neurooncología
Pfizer

Completed

Safety and Efficacy of PD0332991 (Palbociclib), a Cyclin-dependent Kinase 4 and 6 Inhibitor, in Patients With Oligodendroglioma or Recurrent Oligoastrocytoma Anaplastic With the Activity of the Protein RB Preserved

Oligoastrocytoma | Oligodendroglioma

Spain
Georgetown University
Pfizer

Unknown

PD-0332991, 5-FU, and Oxaliplatin for Advanced Solid Tumor Malignancies

Advanced Solid Tumor Malignancies

United States
Cancer Institute and Hospital, Chinese Academy...
OrigiMed

Unknown

Predicted Biomarkers of CDK4/6 Inhibitors (Palbociclib) in ER-positive Metastasis Breast Cancer

Breast Cancer

China
Spanish Breast Cancer Research Group
AstraZeneca

Active, not recruiting

Fulvestrant (F)+Placebo vs F+Palbociclib First Line for Postmenopausal Hormone Receptor+ Advanced Breast Cancer (FLIPPER)

Breast Neoplasms

Spain, Ireland
Royal Marsden NHS Foundation Trust
Pfizer; Roche Pharma AG; Institute of Cancer Research, United Kingdom

Unknown

PIPA: Combination of PI3 Kinase Inhibitors and PAlbociclib (PIPA)

Breast Cancer | Advanced Solid Tumours

United Kingdom
Pfizer

Completed

Study Of Letrozole With Or Without Palbociclib (PD-0332991) For The First-Line Treatment Of Hormone-Receptor Positive Advanced Breast Cancer

Breast Cancer

Korea, Republic of, United States, Spain, Germany, Ireland, Hungary, Canada, France, Italy, Russian Federation, South Africa, Ukraine
Fernando Moreno Antón

Completed

Analysis of Palbociclib Treatment in Patients With Advanced Breast Cancer Within a Compassionate Use Programe (PALBOCOMP)

Breast Cancer

Spain
Weill Medical College of Cornell University
Pfizer; Millennium Pharmaceuticals, Inc.

Terminated

Trial of PD 0332991 Plus Bortezomib in Patients With Relapsed Mantle Cell Lymphoma

Mantle Cell Lymphoma

United States
University of Ulm
Pfizer; National Center for Tumor Diseases, Heidelberg

Unknown

Study of Palbociclib in MLL-rearranged Acute Leukemias

Acute Myeloid Leukemia | Acute Lymphoblastic Leukemia

Germany
Samsung Medical Center

Unknown

A Study of Palbociclib With Exemestane Plus GnRH Versus Capecitabine in Premenopausal Women With HR+ MBC

Metastatic Breast Cancer

Korea, Republic of
Pfizer

No longer available

Expanded Access Study Of Palbociclib (PD-0332991) In Combination With Letrozole As Treatment Of Post-Menopausal Women With HR-Positive, Her2-Negative Advanced Breast Cancer For Whom Letrozole Therapy Is Deemed Appropriate

Advanced Breast Cancer (Female)

Canada, United States
Zhejiang Cancer Hospital

Unknown

The Combination of Palbociclib With ddEC-P as Neoadjuvant Therapy in Triple Negative Breast Cancer (PECP)

Breast Cancer | Breast Neoplasms | Breast Diseases
UNC Lineberger Comprehensive Cancer Center
Pfizer

Terminated

Phase II Trial of Palbociclib in Patients With Metastatic Urothelial Cancer After Failure of First-Line Chemotherapy

Metastatic Urothelial Carcinoma (UC)

United States
Weill Medical College of Cornell University
Pfizer; Celgene Corporation

Terminated

Palbociclib in Combination With Lenalidomide and Dexamethasone for Multiple Myeloma (PD + RD)

Multiple Myeloma

United States
National Cancer Institute (NCI)

Withdrawn

Fulvestrant and Palbociclib With or Without Copanlisib in Treating Patients With Hormone Receptor Positive, HER2 Negative, Stage IV Breast Cancer

Estrogen Receptor Positive | HER2/Neu Negative | Progesterone Receptor Positive | Stage IV Breast Cancer AJCC v6 and v7
Razelle Kurzrock, MD

Withdrawn

Histology-Independent Study of Palbociclib in Patients With Advanced Cancer

Cancer, Advanced

United States
Assistance Publique - Hôpitaux de Paris

Unknown

A Biomarker Study of Palbociclib + Fulvestrant for Second, and Third Line of Postmenopausal Women With hr+/her2- Advanced Breast Cancer (PALPETBIO)

Breast Cancer | Metastasis | HR+/HER2-negative Breast Cancer
GlaxoSmithKline
Pfizer

Completed

A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Anti-Cancer Activity of Trametinib in Combination With Palbociclib in Subjects With Solid Tumors

Cancer

United States
Pfizer

Completed

Study Of Palbociclib (PD-0332991) In Renal Impairment

Renal Impairment

United States
Peking University Cancer Hospital & Institute
Kiang Wu Hospital

Unknown

Efficacy of Palbociclib in Advanced Acral Melanoma With Cell Cycle Gene Aberrations

Melanoma
Pfizer

Completed

A Study To Describe The Effect Of Impaired Hepatic Function Of The Pharmacokinetics Of Palbociclib

Healthy, Hepatic Insufficiency

United States
Grupo Espanol de Tumores Neuroendocrinos

Completed

A Trial to Assess the Activity and Safety of Palbociclib in Patients With Well and Moderately Differentiated Metastatic Pancreatic Neuroendocrine Tumors (pNET) (PALBONET)

Pancreatic Neuroendocrine Cancer

Spain
Samsung Medical Center

Unknown

The Resistance and Immune Response to Palbociclib in Breast Cancer

Breast Cancer Stage IV

Korea, Republic of
Memorial Sloan Kettering Cancer Center
Pfizer

Completed

PD0332991 (Palbociclib) in Patients With Advanced or Metastatic Liposarcoma

Sarcoma | Liposarcoma

United States
Pfizer

Completed

Proton Pump Inhibitor (PPI, Rabeprazole) Effect On Tablet Formulation Of Palbociclib

Healthy Volunteer

United States
Sutep Jaruratanasirikul
Prince of Songkla University

Completed

Piperacillin/Tazobactam in Critically Ill Patients With Severe Sepsis and Septic Shock

Early Phase of Severe Sepsis and Septic Shock

Thailand
Samsung Medical Center

Unknown

A Phase II Study of Palbociclib for Recurrent or Refractory Advanced Thymic Epithelial Tumor

Thymic Cancer

Korea, Republic of
Fondazione Sandro Pitigliani

Completed

To Reverse ENDocrine Resistance Trial - PD 0332991 Monotherapy vs PD 0332991 in Combination With the Endocrine Therapy (TREnd)

Breast Cancer

Italy
Merck Sharp & Dohme LLC

Completed

Comparative Study of Ertapenem Versus Another Antibiotic in the Treatment of Diabetic Foot Infections in Adults (0826-034)

Foot Infections in Diabetic Patients
Gustave Roussy, Cancer Campus, Grand Paris

Completed

Randomized Phase II Study to Assess PD 0332991 in Breast Cancer (POP)

Untreated Operable Early Breast Cancer

France
University of Florida

Completed

Cyclin Dependent Kinase (CDK)4/6 Inhibitor, PD0332991 in Advanced Non-small Cell Lung Cancer NSCLC.

Non-small Cell Lung Cancer

United States
Assistance Publique - Hôpitaux de Paris

Unknown

Phase I-II Study With Tumor Molecular Pharmacodynamic (MPD) Evaluation and Pharmacokinetics of PD-0332991 in Patients Suffering Metastatic Melanoma (OPTIMUM)

Melanoma BRAF V600E/K Mutated | CDNKN2A Loss Defined

France
Pfizer

Completed

A Study Of Oral Palbociclib (PD-0332991), A Cyclin-Dependent Kinase Inhibitor, In Patients With Advanced Cancer

Neoplasms | Lymphoma, Non-Hodgkin

United States
Pfizer

Completed

An Investigational Study Drug, Palbociclib (PD-0332991), Is Being Studied In Patients With Mantle Cell Lymphoma. Patients Must Have Received Prior Treatment(s) For Mantle Cell Lymphoma.

Lymphoma, Mantle-Cell

United States
Pfizer

Completed

Drug Interaction Study To Investigate The Potential Effect Of Proton Pump Inhibitor On The Pharmacokinetics Of Palbociclib (PD-0332991)

Healthy

United States
Pfizer

Completed

A Study To Determine If Coadministration Of Tamoxifen Alters The Extent Or Rate Of Palbociclib (PD-0332991) Absorption Or Elimination In Healthy Male Volunteers

Healthy

United States

3

Subscribe